Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of CAPRELSA is substantial. |
Clinical Added Value
| minor |
The transparency Commission considers that CAPRELSA provides a minor improvement in the actual benefit (IAB level IV) in the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. |
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
RygaabCkJz8WNMqz
Listen
